

Immunohematology Case Studies 2016 - 5

PD Dr. med. Franz F Wagner Red Cross Blood Service NSTOB fwagner@bsd-nstob.de

Clinical History



A 78 yrs old patient had coronary artery bypass surgery.

- In the perioperative period, she received 14 red cell units (A Rh pos) within 1 week.
- Antibody screen remained negative throughout.

Three weeks later, she had severe pneumonia and was on artificial ventilation.

An antibody screen was requested when the patient had hemoglobin 8 g/dl.

This antibody screen was positive.

```
Serologic History
```



Initial presentation:

Blood type A Rh: D+ C+c+E-e+ (CcDee, R1r) Kell: K-Antibody screen (3 cells): negative (IAT + neutral)

All transfused units were A CcDee K-

Current Sample Presentation Data



ABO/Rh: A Rh pos DAT: negative Antibody Screen Method: IAT (BioRad ID gel) Antibody Screen Results: positive (0.5 to 1+) Antibody Identification Method: IAT (BioRad ID gel) Antibody Identification Preliminary Results: Almost all cells weak positive, autocontrol negative Challenge with the Current Presentation



Based on the initial panel this case is of category "autocontrol negative / almost all cells positive"

This constellation suggests that transfused red blood cells might not be compatible and requires further, often laborious work-up.

Panel



-				- 7	1	Rh	-Hr						K	ell	05.0	4.50	Duf	fy I	Kida	1 1	Lew	is	P		MNS	5	L	the	г. Х	٩¢		
Ī	Rh-Hr	ID	0.1	D	調査田	調えて	and the	0	意味		XI	k	Kp	Kp	Current Car	S NA	新 EV	y [#] J	1.5	k ^e L	in de	(in the	Sector Sector	M	18122	V/EP/N	語見し	おおい	Marx.			E
	R1 ^w R1	170744	+	+	0	0	+	÷	1	1	0	+	0	+	1	+	識	ő -	+ (0	0	0	0	0	and and	ALC: N	0		100		Co(b+)	+
2	R ₁ R ₁	331530	+	+	0	0	+	0	1	1	+	+	0	+	0	+	0	÷. () ·	+	0	+	+	the second	DV II	0	0		1000	Ě	Bg(a+) Do(a+b+)	+
3	R_2R_2	384848	0	+	+	+	0	0	1	1	+	+	0	+	0	+		()).	+	+	0	+	0	Ser al		_	V	V Ball	0	Bg(a+)	7.
4	Ro	074858	0	+	0	+	÷	0	1	1	0	+	0	+	0	+	Ö	÷ (0.	+	0	÷	_	the second second	and descent		1) -	-	新生	Co(b+)	.+
5	ר'ר'	1783510	+	0	0	0	+	0	1	1	0	+	0	+	1	+		0 -	+ -	+	0	+	+	0			A LEASE) -	1000			+
6	r"r"	732530	0	0	+	+	0	0	1	1	0	+	0	+	1	+	0	調査・	+ .	÷	0	÷	+	+ () A	. 0) -		家市		+
1	rr	329238	0	0	0	+	+	0	1	1	0	+	0	+	0	+	0		+ -	+	0	+	4	i i		計) -		0		オ
8	rr	303099	0	0	0	+	+	0	1	1	0	+	÷	+	0	+		Ó (2	+	0	+	+	設計			1) -		0		+
9	π	1703902	0	0	0	+	+	0	1	1	+	0	0	+	1	+	雜	0.	+ -	+	0	+	0	日本	書いた	+ 0	1	-		主		+
10	m	331559	0	0	0	+	+	0	1	1	0	+	0	+	0	+		÷.	+	0	0	+		Contract of the local division of the local	地でも	_	1) -	- House	0	Bg(a+)	+
ñ	R _z R ₁ ^w	356770	+	+	+	0	+	+	1	1	0	+	0	+	0	+	0		+	+	+	0	+	辞				- I	Photos:	0		+
12	R _z R ₂	202024	w	+	+	+	0	0	1	1	+	+	0	+	0	+		<u>o</u> .	+ -	+	+	0	+	0) -	- AND	+		+
13		143225	0	0	0	+	+	0	1	1	0	+	0	+	0	+	And Marked Mark	÷ (+	0	+		0			-		- NAR	調	Bg(a+)	ナ
福	r ^w r	1779780	+	0	0	+	+	+	1	1	+	+	0	+	1	+	素	0.	+	0	0	+	0	÷		5	(- Andrew			4
15	R ₂ r	1718113	0	+	+	+	+	0	1	1	0	+	0	+	0	+	题	調し.	+	+	0	+	0	大学			AL MAN	- (4		+
16		382612	0	0	0	+	+	0	1	1	+	+	0	+	0	+		龗.	+	0	0	+	0	Ser and a sec an		ġ.	1) -	- ANGE	\$	Wr(a+) Bg(a+)	1

All cells positive independent of the antigen constellation!

Challenge with the Current Presentation



The most frequent causes for the "autocontrol negative / almost all cells positive" pattern are:

- An antibody to an antigen of high prevalence
- A combination of antibodies to "the usual" antigens
- An antibody interfering with the commercial cell preparation
- An autoantibody with a suppressed autoantigen

\rightarrow The laboratory did some additional work

Panel




No. Nr. N°	Rh	Donor Spender Donneur Donatore	Ag = antigen Other Andere / Autres Altri / Otros				Rhe	!SUS					M	NS	一日中間	P	Le	wis	Luth	erán		K	ell		Du	ffy	KJ	dd	Sex linked	No. Nr. Ұ Szám Br.	0 2.3
- N° Szám Br.		Donante Davatelj Doador Giver	Andet / Egyéb Ostalo / Outros Andre	D	с	E	с	e	f	C,	v	M	N	S	s	Pı	Le"	Le ⁵	Lu"	Lub	ĸ	k	Kp*	Js ^a	Fy*	Fyb	Jk*	Jk ³	Xg ^a	の語言	
SC I*						1.5										2			1	15				1.36		1	34-1	nu.	Sec. 24	SC I*	
SC II*	at a fair		AND DE M										1									1		ar t	. in	12	7 H)	3.40	12702-	SC II*	
SC III*											1			the a									1	R	r #j	1.5		19	-127-	SC III*	
-1	IT	M3284TR		0	0	0	+	+ f	+	0	NT	0	+	0	+	0	+	0	0	+	0	+	0	0	0	÷.	+	÷.	+	$\frac{1}{2} = \frac{1}{2} \sum_{i=1}^{n-1} \frac{1}{2} \sum_$	(f)
2	II-	- M3133CE	and the second second	0	0	0	+	+	+	0	0	÷	0	+	+	+*	0	+	0	+	+	+	0	0	0	÷	+	+	0	÷ 2	-
3	IT.	M3266CC		0	+	0	+	÷	+	0	NT	+	+	+	0	+	0	+	0	+	0	- + *	-0	0	3 4	+	0	+	+	. 3	- "
- 4	I"r	M3440HM		0	0	+	+	+	+	0	NT	+	+	+	+	+	0	+	0	+	0	+	0	0	+	+	. 0	+	+	4	(+)
5	п	MBOBSHM	(Kp(a+)	0	0	0	+	+	+	0	0	+	+	÷	+	+	0	+	0	+	0	÷	+	0	,÷.	- 4 -	++	0	+	5	
6	R		Co(5+)	+	0	0	+	4	+	0	NT	4	0	+	+	0	+	0	0	+	0	+	0	0	+	0	+	+	+	6	(+)
7	R _i R _i	M3199CC		+	+	0	0	+	NT	0	NT	+	+	+	+	+	+	0	.t.	+	0	+	0	0	+	+	+	0	*+	7	P
8	R _i R _i	M2T45HM		+	+	0	0	+	NT	0	NT	+	0	÷	+	+	0	+	0	+	+	+	0	0	4	÷	0	+	0	8	+
9	R,R,* .	M596CC		+	+	0	0	+	NT	+	NT.	0	+	0	+	0	0	+	0	+	+	+	.0	0	÷	0	0	+	+	9	(+)
- 10 -	R.R	M3358HE		+	0	÷	+	0	NT	0	NT	+	+	+	+	+	0	+	0	+	0	+	0	0	+	+	0	+	+	= 10	P
11	in .	M3344CC		0	+*	0	+	+	+	0	NT	+	+	+	+	+	0	0	0	+	0	+,	0	0	0	+	+	+	+	11	(+)
Auto										1						1											0			Auto	

In another panel, there were some weak to negative cells There was no obvious correlation with the antigen pattern

note: antigen typing was considered confounded by recent massive transfusion


Influence of ABO type and test conditions





Agglutination at 20° C and 4° C with 4 test cells type A1 and 4 test cells type O ("H")

There was no correlation with ABO type



Autocontrol ("EK") and reactivity with 3 cell antibody screen in the following techniques: Neutral (NaCl), Liss, 4° C saline, standard ID, PEG and Albumine

In the cold, there was non-specific reactivity. Albumin-IAT was positive

Panel



	SYSTEM			R	h - I	Hr					ŀ	Kell			Du	iffy	Ki	dd	Le	wis	Ρ		Μ	N		Luth	eran	Xg	Special Antigen Type	
	Donor	D	С	c	E	e	V	C*	к	k	Kp	Kp	Js*	Jsb	Fy	Fy⁵	Jk*	Jk⁵	Le*	Le°	Ρ1	М	N	S	s	Luª	Lu ^b	Xg⁺a		D
1	R1wR1 B4749	+	+	0	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	+	+	+	+	0	+	0	÷	0		P
2	R1R1 B9193	+	+	0	0	+	0	0	+	+	0	+	0	+	+	0	+	+	+	0	+	+	0	+	0	0	+	0		(4)
3	R1R1 B7357	+	+	0	0	+	0	0	0	+	0	+	0	+	0	+	+	0	0	+	0	+	0	+	0	0	+	+	Sc:2	(4)
4	R1R1 B8224	+	+	0	0	+	0	0	0	+	0	+	0	+	+	0	+	0	0	+	0	0	+	+	+	0	+	+		6)
5	RzR1 A3909	+	+	0	+	+	0	0	0	+	0	+	0	+	+	+	+	+	+	0	+	0	+	+	+	0	+	+		6)
6	RzR2 A4210	+	W	+	+	0	0	0	0	+	0	+	0	+	0	+	+	0	0	+	+	+	0	+	+	0	+	0		+
7	R2R2 C1461	+	0	+	+	0	0	0	0	+	0	+	0	+	+	+	0	+	0	+	÷	0	+	0	+	0	+	+	Yt(b+)	(4)
8	R2R2 C6003	+	0	+	+	0	0	0	0	+	0	+	0	+	+	0	0	+	0	+	+	+	+	+	+	0	+	+		(4)
9	R2R2 C6000	+	0	+	+	0	0	0	0	+	0	+	0	+	÷	+	+	+	+	0	+	+	0	0	+	0	+	+		6)
10	R1wR1 B7306	+	+	0	0	+	0	+	0	+	0	+	0	+	+	0	0	+	+	0	0	+	+	÷	0	0	+	+		(4)
		D	С	c	E	e	V	C*	ĸ	k	Kp	Kp	Js*	JsÞ	Fy	Fy	Jk*	Jk	Le*	Le⁵	P1	М	N	S	s	Lu	Lu	Xg	· 合体、推荐 · 》 · 注	法に
11	r'r E974	0	+	+	0	+	0	0	0	+	0	+	0	+	+	+	+	+	0	+	0	0	+	0	+	0	+	+		6)
12	r"r F660	0	0	+	+	+	0	0	÷	0	0	+	0	+	+	0	0	+	0	+	+	+	+	0	+	0	+	+		(+)
13	rr H1352	0	0	+	0	+	0	0	0	+	0	+	0	+	+	0	+	+	+	0	+	0	+	+	+	0	+	+		+
14	r'r E621	0	+	+	0	+	0	0	0	+	0	+	0	+	+	0	0	+	0	+	+	+	0	+	0	0	+	+		+
15	rr N4189	0	0	+	0	+	0	0	0	+	0	+	0	+	0	+	0	+	+	0	+	0	+	0	+	0	+	0		P
16	rr H1720	0	0	+	0	+	0	0	0	+	0	+	0	+	+	0	+	0	0	0	+	+	+	0	+	+	+	+		+
17	rr G1327	0	0	+	0	+	0	0	+	0	0	+	0	+	+	+	+	+	0	+	+	+	+	0	+	0	+	0		(1)
18	rr H1721	0	0	+	0	+	0	0	0	+	0	+	0	+	+	0	+	0	0	+	0	0	+	0	÷	0	+	+		(F)
19	rr N4010	0	0	+	0	+	0	0	0	+	0	+	0	+	0	+	+	+	0	+	0	0	+	+	0	0	+	+		E
20	Ror D1196	+	0	+	0	+	+	0	0	+	0	+	0	+	0	0	+	+	+	0	+	+	+	0	+	0	+	+		+

A third panel was done but did not give much additional information

Challenge with the Current Presentation



Based on the three panels, the following explanations are unlikely:

- An antibody to an antigen of "really" high prevalence, like Vel, Lu^b, Kp^b, Yt^a
 - For these antigens, all cells would be expected to be positive
 - In addition, there was no correlation Lu^a and Kp^a status
- A combination of antibodies to "the usual" antigens
 - In that case, a pattern would be expected

Crossmatch



Konserven-Nr	AB0 Rh-Formel	Kell	Antigene	Ala	th?	FS	FG	Ś	ğ.	MI	N	B
2331 125	\square	-		ľ	ľ		~					14)
2327740		-										(+)
2331 165		-	×									(+)
2327754	A+ M	-										P
23 26 775	11	-	1	1	#	Zut	7	1	4	14	2	-
23 51 538		-										+
23 03 787		-										(+)
23 34 354		-										(+)
23 07 558		-										(+)
23 26 773		-									_	(+)

Crossmatches with ABO / RH compatible units (all A R1r) were mostly positive:

Only 2 of 40 units were negative

Crossmatch



Konserven-Nr	AB0 Rh-Formel	Kell	Antigene	Jug	pis	FS	FG	Ś	ġ.	M	N	D
2331 125	\bigcap	-		Ĩ	Ĩ							14)
2327740		-										(+)
2331 165		1	×									(+)
2327754	A+ M	-										P
23 26 775	11	-		II. X	#	Z	7	1	100	14	2	-
22 51 538		-										+
23 03 757		-										(+)
23 34 354		-										(+)
23 07 558		-										(+)
23 26 773		-										(+)

Crossmatches with ABO / RH compatible units (all A R1r) were mostly positive:

Only 2 of 40 units were negative

The positive crossmatch with ABO-identical cells is an argument against

- antibodies to commercial test cells
- antibodies to blood O cells (e.g. anti-IH)

Crossmatch



Konserven-Nr	AB0 Rh-Formel	Kell	Antigene	Ala	12º	EFS	54	Ś	ġ.	M	N	D
2331 125	\square	-		ľ	ľ							14)
2327749	1/	1										(+)
2331 165		-	×									(+)
2327754	A+ M	-										P
23 26 775	11	-		1ª	1	X	7	1	100	14	1	-
23 51 538		-										+
23 08 673		-	k									(+)
22 53 309		-		X	ther	1-	X	X	1ª	1	Att	-
23 32 834		-			1							(+)

The two compatible units differed in their antigen pattern

- Another argument against a combination of antibodies to "conventional" antigens

Interim Antibody Identification Possible Answers and Next Steps



The laboratory suspected an antibody to an antigen of higher to high frequency.

Therefore, two additional tests were done:(1) Cross-match with rare cells(2) Neutralization with plasma

Crossmatch with rare cells



Konserven-Nr	AB0 Rh-Formel		Kell	Antigene		D
Yta-g-Zelli	BG: 0	Nr.	160	р.		+
yta-g-Zelle	BO: O	i 1	474			+
Yh-g-Zelle		*1	Λ	×		+
Yle"-9-Zelle		11	22	2		+
Kna- Ø-Zelle		" (493	1		+
Kna-Ø-Zelle	36 0	u	525			+
12pb - 0 - 2010		(]	491			+
Kpb - & - 200	e BG:0	10	529			+
lan - & - 7d		(1	323			(4)
lan = 9-70	-	11	542			+

All available rare cells showed a positive cross-match

Crossmatch with rare cells

Konserven-Nr	AB0 Rh-Formel		Kell	Antigene		T	
Yta-g-Zelli		Nr.	160	, and a second sec			$\overline{14}$
4 ta- 9- Zelle	- BG: 0	11	474				+
Yhe-g-Zelle		*1	Λ	×			+
Y2°-9-2dle	BG A	11	22	2			+
Kn- &-Zelle	BG: A	"1	493	1			+
Kna-g-zelle		u	525				+
Kpb-g-Zelle		()	491				+
kpb - & - 200		11	529		1		+
lan - & - tel	Le BG:0	4	323				(4)
lan = 9-20		11	542				+

All available rare cells showed a positive cross-match

The ability to identify an antibody to an antigen of higher frequency heavily depends on the "rare" cells available in a laboratory.

In the case shown, only Yt^a, Yk^a, Kn^a, Kp^b and Lan were tested. Yk^a and Kn^a have a frequency of 98% resp. 92% and would have fitted the "all positive with some negative" pattern.

	Ne	eutr	3	al	i	Z	3	at	:i(0	r	ׂן (V	Vİ	it	ł) k	כ	S	15	Sľ	Y	15	a						ηc) []	ſ	
Ce Ce	ellbin ellbin	d ID16 d ID16 d ID16 n pane	-P I 1				TC	80 n.a 80	002 1. 002		109 105	c c	e)344)344)344)344	1 1		1	S.	5.L	Q	Ş	36	-	3			3 2		S	anqui	ſ	Reagents Plesmank 1066 CX The Neth	an 125 Amster		5	Phon Fax: reage www
					i.		-Hr				and the second		Ke	1			Duffy		idd	_	wis	P		MNS	5]	Lut	her.	Xg							\$	2
	Rh-Hr	- ID	51.4	Q1 IS	应该能	动物	いいます	Option of	語い		X	ĸK			S. S	JS ^D	近 EV EV	Jk	Jk	in the second	Le Le	Sector Sector	M	N.V.	VIEN.	Lū	語記	Xg,					12	d	16	40
	R1 ^w R1	170744	+	+	0	0	+	÷	1	1	0	+	0	+	1	+	截 0	+	0	0	0	0	0	the second		0	+	新	Co(b+)				-	-	(+)	(ϵ)
2	R1R1	331530	+	÷	0	0	+	0	1	1	+	+	0	+	0	+	0; ±	0	+	0	÷	+	業	in the second	£ 0	0	+	·	Bg(a+)	Do(a+b-	+)		1	-	+	+
(c) (c)	R_2R_2	384848	0	÷	+	+	0	0	1	1	+	+	0	+	0	÷		0	+	+	0	+	0	THE REAL		0	w	0	Bg(a+)				1		+	+
14.16	Ro	074858	0	+	0	÷	÷	0	1	1	0	+	0	+	0	+	0 +	0	+	0	+	0	0	市土		0	+	建	Co(b+)					F	+	+
麗	r'r'	1783510	+	0	0	0	+	0	1	1	0	+	0	+	1	+	÷ 0	+	+	0	+	+	0	÷	調料	0	+						4	-	+	+
6	r"r"	732530	0	0	+	+	0	0	1	1	0	+	0	+	1	+	0 +	+	+	0	+	+	1. A	0	t õ	0	+	海					3	F	+	+
	rr	329238	0	0	0	+	+	0	1	1	0	+	0	+	0	+	-0. +-	+	+	0	+	÷	0	王	0+	0	+	0	-				2	7	+	+
ŝ	rr	303099	0	0	0	+	+	0	1	1	0	+	+	+	0	+	÷0	0	+	0	+	+	業出	11-1-1	0 +	0	+	0					-	+	+	+
9	rr	1703902	0	0	0	+	+	0	1	1	+	0	0	+	1	+	生。	+	÷	0	+	0	Ŧ	記して	± 0	+	+	主					-	F	+	+
10	rr	331559	0	0	0	+	+	0	1	1	0	+	0	+	0	+		+	0	0	+	+	0	副が	程-0	0	+	0	Bg(a+)				1	_	X	F
and the	R _z R ₁ ^w	356770	+	÷	+	0	÷	+	1	1	0	+	0	+	0	+	0 +	+	+	+	0	+	÷	+	C. -	0	÷	0					-	F	(+)	(f)
売間 (12)	R ₂ R ₂	202024	w	+	+	+	0	0	1	1	+	+	0	+	0	+	至 0	+	+	+	0	+	õ.	N +	C. +	0	+	3			-		-	F	+	+
13	rr	143225	0	0	0	+	+	0	1	1	0	+	0	+	0	+	0 ±	0	+	0	+	+	0	Sint.	Č: ut	+	-	1954milt	Bg(a+)	10			-	F	+	+
14	r ^w r	1779780	+	0	0	+	+	+	1	1	+	-	0	+	1	+	法。	4	0	0	+	0	業士	Ô.	ő +	0		空					4	-	+	+
15	R ₂ r	1718113	0	+	+	+	+	0	1	1	0	+	0	+	0	+	聖書	+	+	0	+	0	業	COLUMN TWO IS NOT	6+	+		臣					+	-	+	+
16		382612	0	0	0	+	+	0	1	1	+	+	0	+	0	+	潮離	+	0	0	+	0	24 4	+	o +	0	+	龗	Wr(a+)	Bg(a+)			1	K	NT	+

Neutralization with plasma



Some blood group antibodies are directed to proteins that are abundantly present in plasma. The by far most important example is the CH/RG blood group system:

Ch antigens are on complement C4B, Rg antigens are on complement C4A

These antibodies are inhibited by plasma Although both specifities would fit the pattern, no inhibition was observed



The case was referred to our laboratory



The case was referred to our laboratory

Which tests should be repeated? Is there any test lacking that we would have done? Did the colleagues miss some special condition?



Which tests should be repeated?

Decision 1: Let's do our basal diagnostics, because we know how to interpret these tests

1: ABD Conf Angefordert: Dorner / 12:05:2016: 08:06:01 Gelestet: Innova J/02-3422/12:05:2016: 08:55:05	10002996 002996 1 2 3 Anti-A Anti-B Anti-D ++++ 0 ++++	
1: 8BVSF Poly Angefordert: Damer / 12:05:2016:08:06:01 Geteslet: Kroll/12:05:2016:09:11:48	22. 032061 032061 032061 2 3 4 AKS 1 AKS 2 AKS 3 0 (*) 0	
1: Auto Poly Angefordert: Domer / 12.05.2016 08:06:01 Getestet: Kroll/12.05.2016 09:11:53	22. 032061 1 Auto Ctrl (+)	
1: 8Fic ABScr Angefordert: Domer / 12.05.2016 08.07.02 Getestet: Kroll/12.05.2016 09.30.40	55. 018059 018059 018059 018059 018059 1 2 3 4 5 AKS 1 AKS 2 AKS 3 AKS E1 AKS E2 (+) (+) (+) 0 0	018069 6 AKS E3 0

Tests were done in BioVue technique using AutoVue Innova:

[ABD Conf - ABD confirmation; 8BVSF Poly - 3 cell antibody screen in IAT; Auto Poly - autocontrol in IAT; FicABScr - 3 cell antibody screen in IAT (left) and with ficin-treated cells on neutral column (right)]



Which tests should be repeated?

Decision 1: Let's do our basal diagnostics, because we know how to interpret these tests

061	54.52.x 44.52.x 54.52.x					D	C	E	c	e	C.	ĸ	k	Kp°	Кр⊳	Jsª	Js	Fy	Fy	Jk	Jkt	Le	Le	Pı	м	N	s	s	Lu ³	u۴	Xg	1.	Able	ser	2.	Ables	ser
	In succession in the local division in the l		214			r.												6							576	1963						pAHG	PAP	4°C	pAHG	PAP	4*
	-	_	-	D.e	e	+	+	0	0	+	÷	0	+	0	÷	nt	nt	0	15	0	+	0	+	0	×.	0	D	憲	0	+	0	4	0	0	(+)	0	C
	1 0	cD	.EE			+	0	÷	÷	0	0	0	+	0	+	nt	nt		記録	+	0	+	0	te	÷		0	¥.	+	+	-	4	0	0	(4)	6	0
	III. (cd	dee	•		0	0	0	÷	÷	0	÷	÷	0	÷	nt	nt	÷	0	+	+	0	+	0	0	*	*	0	0	+	0	0	0	0	0	0	0
																					-	-		-	TAP			10.00	-	EM	(:	0	0	0	6		0
		D	С	E	C	e	C	к	k	Кр*	Кры	Jsª	Js°	Fy ^a	Fy®]k₃	Jk ^e	Le°	Le	Pı	м	N	s	s	Lu*	LU ⁶	Xgʻ					pAHG	PAP	4°C	pAHG	PAP	4*
I	CCC ^W D.ee	F	+	0	0	÷	+	0	+	0	+	nt	пt		Ő	+	0	÷	0	Ð			Ū.		0	÷	観光			1	1	by	0	1	(#)	0	-
Ì	CCD.ee	÷	+	0	0	+	0	÷	÷	0	+	nt	_	0	Base	÷	0	+	0	0	Ö.	1	0		0					2	2	A	0	-	(4)	0	-
I	ccD.EĖ	+	0	+	+	0	0	0	+	0	+	nt		語を	0	0	÷	0	+	÷	の実施	0		i.	0		0			-	3	u.	0	<u> </u>	+	8	-
Ì	Ccddee	0	+	0	+	+	0	0	+	0	+	nt				0	+	0	+	+	0		0		0	+	のたた	-	4.	4	1	10 to	0	-	+	0	-
Ì	ccddEe	0	0	+	+	+	0	0	+	0	+	nt		2.341	の変換	+	0	0	+	-		0		0	0		¥.	-		6	5	W	0	-	+	R	-
P	ccddee	0	0	0	+	+	0	+	+	0	-	-	nt	1000		+	0	0	0	+	0	協力に	Ō.		0				-	6	5	6	0	<u> </u>	(+)	0	-
ř	ccddee	0	0	0	+	+	0	0	+	+	+	nt	_		22.5	+	+	+	0	0		0	0		0	-	791	Co(h+1	*		(4)	0	-	t	8	
Ì	ccD.ee	+	0	0	+	+	0	0	+	0	1	-	·	0		+	0	0	+	+	14				0		0	000		8		-	0	-	1 .	ð	-
	ccddee	0	0	0	+	+	0	0	+	0	-	-	_	SHO N	10111-00	0	+	0	0	- 64	0		0		0	_	-					4	0	-	(+)	X	
		-	-	-	-	-	-					-					-	0	-	0	6.00	たい	300	麗祭	-	-		-	-	-	-	J.	0	-		X	
	ccddee	0	0	0	+	+	0	0	+	0	-	nt				+	0	-	+		141	0	2	0	+	+	変換の	_	_	1		4	0		+	A	
	ccddee	0	0	0	+	+	0	0	+	0	+	nt	nt	編		0	+	0	+	÷	0.	÷		0	0	+		<u> </u>		1		t	0		+	0	

Legend: Test were done in IAT (pAHG), papain-IAT (PAP) and Neutral 4° C; results were independently scored by two persons ("1. Ableser" and "2. Ableser")



Decision 1: Let's do our basal diagnostics, because we know how to interpret these tests

- → Confirmed: The antibody reacts with almost all cells
- \rightarrow New:

The antibody does not react in direct agglutination in the cold

 \rightarrow New:


The antibody did not react

- with papain-treated cells in IAT
- with ficin-treated cells in direct test



Is there any test lacking that we would have done? Our scheme for antibodies to high frequency antigens includes the following additional tests:


- Typing by molecular and serologic methods for "usual" antigens
- Neutralization with recombinant proteins
- Use of a commercial "special cell" panel



For molecular typing, we used a "exploratory" in-house single SNP method. This method suggested that the patient could form an anti-Jk^b and anti-S. The serologic typing was in concordance, showing only weak reactivity with anti-Jk^b and anti-S (a remnant of the massive transfusion)

In addition, molecular typing suggested that the patient was likely positive for Vel, Lu^b, Yt^a and Kp^b

As the pattern was not suggestive of a mixture of antibodies, no further genotyping was instituted



We have some recombinant proteins available for neutralization.

The set-up is similar to neutralization with plasma:

Patient plasma is first incubated with recombinant protein (or saline control), the mixture is than used for a normal IAT.

For the test, we use cells compatible for DCcEe, K, Jk^a/Jk^b, Fy^a/Fy^b, Ss in order to prevent masking by these antibodies.

All tests remained reactive, hence no antibody specificity was identified.

"Special cell" panel

		System		in the main	1		Rh	- Hr		12		K	ell	1	Du	iffy	Ki	dd	Lev	vis	P	15	MI	NS .		Xg	Luth	eran	Domt	work	Aub	mer		Res	sults	
	Rh -	Hr	Component Lot	Spezial-Antigene Special types	D	с				C.	к		Kp°	Kp ^b	'Fy'	Fy ^b	Jkª	Jk ^b	Le	Le ^s	P ₁		N			Xgª	Lu	Lub	Do	Do ^b	Au"	Au ^b		IAT		
	ccddee	rr	70216320004S	Wr(a+)	0	0	+	0	+	0	0	+	0	+	+	0	0	+	0	+	0	+	+	+	+	+	0	+	+	+	+	+	1	H	#	1
	CCD.ee	R1R1	701124006715	Sc:2+** Yk(a-)*	+	+	0	0	+	0	0	+	0	+	+	+	+	0	0	+	+	+	0	+	+	+	0	+	+	+	nt	nt	2	(4)	(4)	1
	ccddee	rr	701121320745	Lu:14+ ^{+\$} Kn(a+ ^{vw}) [§]	0	0	+	0	+	0	+	+	0	+	1+1	0	~+-	0	0	+	+5	+	0	0	+	4	0	+	0	+	+	0	3	0	0	1
	C ^w cD.ee	R1 ^w r	701122535105	Di(a+)* ⁵ Ch(a-) ⁵	+	+	+	0	+	+	0	+	0	+	+	0	+	+	0	+	+	+	+	0	+	+	0	+	0	+	nt	nt	4	y	#	1
	ccddee	rr	70212345467S	Mi(a+) ^{\$} Bg+ ⁸	0	0	+	0	+	0	0	+	0	+	+	+	+	0	0	0	+	0	+	0	+	0	+	+	0	+	nt	nt	5	¥.	+	1
	C"CD.ee	R1 ^w R1	703121043595	Vw+ [≸] Kn(a+ ^{vw}) [§]	+	÷	0	0	+	+	0	+	0	+	+	0	0	+	0	÷	+	+	+	0	+	+	0	+	0	÷	nt	nt	6	¥.	#]
	CCD.ee	R1R1	70112130887S	Yt(a-)*5 Lu:14+*5	+	+	0	0	+	0	+	0	0	+	+	0	+	0	+	0	+ ^s	+	+	+	+	0	0	+	+	+	+	0	7	Y	#	
	CcD.ee	R1r	702123103945	Co(a-)*	+	+	+	0	+	0	0	+	0	+	+	+	+	0	0	+	0	+	+	0	+	+	0	+	0	+	+	0	8	4	+	
	ccddee	rr	70212252400S	Lu(a-b-)*5 AnWj-*5, Bg+5	0	0	+	0	+	0	0	+	0	+	0	+	+	+	÷	0	+	+	+	0	+	+	0	0	+	0	+	0	9	4	#	1
0	C*CD.ee	R1 ^w R1	702121340495	Ch(a+ ^{vw}) [§] Kn(a+b+)*	+	+	0	0	+	+	0	+	0	+	+	0	+	+	0	+	+\$	0	+	0	+	+	0	+	0	+	nt	nt	10	y	Ħ	
1	ccddee	rr	702129111565	Rg- ⁵	0	0	+	0	+	0	0	+	+	+	0	+	0	$\stackrel{\times}{+}$	0	0	+	+	0	0	+	+	0	+	+	0	nt	nt	11	0	0	1
2	ccD.ee	Ror	85212562614S	Vel-*9	+	0	+	0	+	0	0	+	0	+	0	+	+	+	0	+	+	+	0	0	+	+	0	+	0	+	nt	nt	12	0	0	K

As part of our work-up, we use a special cell panel that includes many cells with rare phenotypes. Two cells were negative:

- one cell marked as Lu:14+ Kn(a+vw)

- \rightarrow Anti-Lu8???
- → Anti-Kn^a???

(should have been inhibited by LU-protein) (should have been inhibited by KN-protein)

- one cell marked as Rg-

→ Anti-Rg???

(should have been inhibited by C4A and by plasma)



What did we miss?



What did we miss?

→ The "many positive, some negative pattern" is extremely suspicious for an antibody in the CH/RG or KN blood group system

→ Anti-Kn^a (and anti-Lu8) are expected to be reactive in papain-IAT

→ Anti-Rg would fit the pattern perfectly, but should be neutralized by plasma or C4A




What did we miss?

- → Anti-Rg would fit the pattern perfectly, but should be neutralized by plasma or C4A
- → Anti-Rg often shows a HTLA pattern ("high titer low avidity")
- \rightarrow Apparently, a titer was lacking in the work-up.




What did we miss?



- \rightarrow Antibody titer was 1:1024
- → Was it "too much antibody" for our neutralization reagents?
- \rightarrow Neutralization was repeated with diluted plasma



What did we miss?



1:2 1:4 1:8 1:16 1:32 1:64

The typical "high titer low avidity" pattern is seen: Reaction at 1:2 is only faint (even in gel technique). The reactions remain unchanged up to a 1:64 dilution

Conclusions



What did we miss?


Alusana 1:128 Voltanal Zelle Z KP								
C4A	C4B	Kn	Inb	Lu(b)	Croma	Yt(a)	Do(a)	Do(b)
0	(† /	(+)	(1)	(+1	(+1	(47	(+1	(7)

- → Neutralization was repeated with diluted plasma (1:128)
- → C4A specifically neutralized the diluted antibody
 → The anti-Rg hypothesis was correct!

Conclusions: *Neutralization of diluted plasma*



What did we miss?




- → Neutralization was repeated with diluted plasma (1:128)
- → C4A specifically neutralized the diluted antibody
 → The anti-Rg hypothesis was correct!

Conclusions: Neutralization of diluted plasma



What did we miss?



→ Plasma did also work with the diluted patient plasma





Anti-Rg is a "generic" name for antibodies to complement C4B

There are two specificities, Anti-Rg1 and Anti-Rg2: Rg1 depends on Val at position 1188 and Leu at position 1191

Rg2 in addition needs Asn at position 1157

The discrimination of Anti-Rg1 and Anti-Rg2 is beyond the capacities of our laboratory. Almost all antisera contain both specificities.

Anti-Rg



Anti-Rg reacts with ~98% of all cells.

It does best react in IAT (in columns) and does not react with papain-treated cells. Typically, there are some cells in a panel that react slightly weaker.

The presence of "weak" or even negative cells in a panel with many positive cells may cause diagnostic confusion and long hunts for possible combinations of antibodies present in the serum.

Anti-Rg



Anti-Rg is considered to be clinically insignificant. There are reports of allergic reactions to plasma or plasma-containing platelet units.

We usually recommend transfusion with antigen positive units tested for compatibility after neutralization with plasma. In addition we try to match for clinically relevant antigens in order to avoid a missed weak yet clinically relevant antibody.

Summary of Case Challenges



This case included several challenges and pitfalls:

- The patient had a recent massive transfusion confounding serologic antigen typing
- The patient had rapidly developed an antibody of very high titer that overwhelmed the usual neutralization capacity of neutralization tests
- The case was referred after considerable prior testing. We had to decide which tests were to be repeated and which results were to be considered valid.

Lessons Learned by the Case



- Neutralization tests may fail, if the antibody titer is extremely high.
- The reaction pattern gives important information. In our case, we were almost certain that the antibody was an anti-Rg because the pattern fitted so well. Therefore, we were eager to repeat the neutralization test.
- Even a clinically irrelevant antibody may harm the patient, because he may not receive the blood units he needs in time
 - In our case, no transfusion was needed



Reid ME, Lomas-Francis C, The blood group antigen facts book

Seltsam A. et al. Recombinant blood group proteins facilitate the detection of alloantibodies to high-prevalence antigens and reveal underlying antibodies: results of an international study. Transfusion. 2014;54(7):1823-30.

Rare Cell Panel: DRK-BSD Identification Red Cell – Special (produced by Red Cross Blood Service BaWü-He)